CXC ELR-Positive Chemokines as Diagnostic and Prognostic Markers for Breast Cancer Patients

SIMPLE SUMMARY: Currently, breast cancer diagnostics do not have readily available diagnostic and prognostic tools, especially in the early stages of the disease. Therefore, there is a constant need to search for tumor markers that can improve current diagnostics. One such molecule that may be a potential marker could be among a group of chemokines. In this work, we summarize reports that evaluate the expression and peripheral blood concentration of ELR-positive CXC chemokines as potential markers and prognostic factors for breast cancer. ABSTRACT: As the most common type of malignant lesison, breast cancer is a leading challenge for clinicians. Currently, diagnosis is based on self-examination and imaging studies that require confirmation by tissue biopsy. However, there are no easily accessible diagnostic tools that can serve as diagnostic and prognostic markers for breast cancer patients. One of the possible candidates for such markers is a group of chemokines that are closely implicated in each stage of tumorigenesis. Many researchers have noted the potential of this molecule group to become tumor markers and have tried to establish their clinical utility. In this work, we summarize the results obtained by scientists on the usefulness of the ELR-positive CXC group of chemokines in ancillary diagnosis of breast cancer.